Literature DB >> 21747115

Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice.

Peizhen Song1, Youcai Zhang, Curtis D Klaassen.   

Abstract

Feeding bile acids (BAs) to rodents has been used to study BA signaling and toxicity in vivo. However, little is known about the effect of feeding BAs on the concentrations of BAs in serum and liver as well as the dose of the fed BAs that causes liver toxicity. The present study was designed to investigate the relative hepatotoxicity of individual BAs by feeding mice cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), or ursodeoxycholic acid (UDCA) at concentrations of 0.01, 0.03, 0.1, 0.3, 1.0, or 3% in their diet for 7 days. The data demonstrate that (1) the ability of the fed BAs to produce hepatotoxicity is UDCA<CA<CDCA<DCA<LCA; (2) the lowest concentration of each BA in the feed that causes hepatotoxicity in mice is CA and CDCA at 0.3%, DCA at 0.1%, and LCA at 0.03%; (3) BA feeding results in a dose-dependent increase in the total serum BA concentrations but had little effect on liver total BA concentrations; (4) hepatotoxicity of the fed BAs does not simply depend on the concentration or hydrophobicity of total BAs in the liver; and (5) liver BA-conjugation enzymes are saturated by feeding UDCA at concentrations higher than 0.3%. In conclusion, the findings of the present study provide guidance for choosing the feeding concentrations of BAs in mice and will aid in interpreting BA hepatotoxicity as well as BA-mediated gene regulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21747115      PMCID: PMC3179674          DOI: 10.1093/toxsci/kfr177

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  29 in total

1.  Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS.

Authors:  Yazen Alnouti; Iván L Csanaky; Curtis D Klaassen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-09-03       Impact factor: 3.205

Review 2.  Biochemical assay of serum bile acids: methods and applications.

Authors:  S A Azer; C D Klaassen; N H Stacey
Journal:  Br J Biomed Sci       Date:  1997-06       Impact factor: 3.829

Review 3.  Nonsurgical management of gallstone disease.

Authors:  D E Howard; H Fromm
Journal:  Gastroenterol Clin North Am       Date:  1999-03       Impact factor: 3.806

Review 4.  Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity.

Authors:  Alan F Hofmann
Journal:  Drug Metab Rev       Date:  2004-10       Impact factor: 4.518

5.  Ischemic preconditioning increases antioxidants in the brain and peripheral organs after cerebral ischemia.

Authors:  Lucio Glantz; Aharon Avramovich; Victoria Trembovler; Vladimir Gurvitz; Ron Kohen; Leonid A Eidelman; Esther Shohami
Journal:  Exp Neurol       Date:  2005-03       Impact factor: 5.330

6.  The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe.

Authors:  Christina M Ambros-Rudolph; Martin Glatz; Michael Trauner; Helmut Kerl; Robert R Müllegger
Journal:  Arch Dermatol       Date:  2007-06

Review 7.  Targeting bile-acid signalling for metabolic diseases.

Authors:  Charles Thomas; Roberto Pellicciari; Mark Pruzanski; Johan Auwerx; Kristina Schoonjans
Journal:  Nat Rev Drug Discov       Date:  2008-08       Impact factor: 84.694

8.  Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid.

Authors:  Anand K Deo; Stelvio M Bandiera
Journal:  Drug Metab Dispos       Date:  2008-06-26       Impact factor: 3.922

Review 9.  Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics.

Authors:  A F Hofmann; L R Hagey
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

10.  Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.

Authors:  Hiroyuki Sato; Antonio Macchiarulo; Charles Thomas; Antimo Gioiello; Mizuho Une; Alan F Hofmann; Régis Saladin; Kristina Schoonjans; Roberto Pellicciari; Johan Auwerx
Journal:  J Med Chem       Date:  2008-02-29       Impact factor: 7.446

View more
  46 in total

1.  Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis.

Authors:  Fei Li; Andrew D Patterson; Kristopher W Krausz; Naoki Tanaka; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice.

Authors:  Youcai Zhang; Pallavi B Limaye; Helen J Renaud; Curtis D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  2014-03-20       Impact factor: 4.219

3.  IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis.

Authors:  Kate M O'Brien; Katryn M Allen; Cheryl E Rockwell; Keara Towery; James P Luyendyk; Bryan L Copple
Journal:  Am J Pathol       Date:  2013-09-05       Impact factor: 4.307

Review 4.  Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.

Authors:  Jessica Tsuei; Thinh Chau; David Mills; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-20

5.  Bile acids regulate nuclear receptor (Nur77) expression and intracellular location to control proliferation and apoptosis.

Authors:  Ying Hu; Thinh Chau; Hui-Xin Liu; Degui Liao; Ryan Keane; Yuqiang Nie; Hui Yang; Yu-Jui Yvonne Wan
Journal:  Mol Cancer Res       Date:  2014-09-17       Impact factor: 5.852

6.  Individual bile acids have differential effects on bile acid signaling in mice.

Authors:  Peizhen Song; Cheryl E Rockwell; Julia Yue Cui; Curtis D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  2015-01-09       Impact factor: 4.219

7.  Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.

Authors:  Justin D Schumacher; Bo Kong; Jason Wu; Daniel Rizzolo; Laura E Armstrong; Monica D Chow; Michael Goedken; Yi-Horng Lee; Grace L Guo
Journal:  Hepatology       Date:  2019-08-09       Impact factor: 17.425

8.  Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids.

Authors:  Aafke W F Janssen; Tom Houben; Saeed Katiraei; Wieneke Dijk; Lily Boutens; Nieke van der Bolt; Zeneng Wang; J Mark Brown; Stanley L Hazen; Stéphane Mandard; Ronit Shiri-Sverdlov; Folkert Kuipers; Ko Willems van Dijk; Jacques Vervoort; Rinke Stienstra; Guido J E J Hooiveld; Sander Kersten
Journal:  J Lipid Res       Date:  2017-05-22       Impact factor: 5.922

9.  TUDCA slows retinal degeneration in two different mouse models of retinitis pigmentosa and prevents obesity in Bardet-Biedl syndrome type 1 mice.

Authors:  Arlene V Drack; Alina V Dumitrescu; Sajag Bhattarai; Daniel Gratie; Edwin M Stone; Robert Mullins; Val C Sheffield
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-05       Impact factor: 4.799

10.  Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice.

Authors:  Benjamin L Woolbright; Feng Li; Yuchao Xie; Anwar Farhood; Peter Fickert; Michael Trauner; Hartmut Jaeschke
Journal:  Toxicol Lett       Date:  2014-04-15       Impact factor: 4.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.